Center-Authored Papers

Filters: Author is Burtness, Barbara  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ et al..  2017.  NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.. Journal of the National Comprehensive Cancer Network : JNCCN. 15(6):761-770. Abstract
C
Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee S-H et al..  2016.  Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
M
Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B et al..  2016.  Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.. The Lancet. Oncology. Abstract
P
Pfister DG, Ang K-K, Brizel DM, Burtness B, Cmelak AJ, Colevas DA, Dunphy F, Eisele DW, Gilbert J, Gillison ML et al..  2012.  Mucosal melanoma of the head and neck.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(3):320-38.
Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas DA, Dunphy F, Eisele DW et al..  2015.  Head and Neck Cancers, Version 1.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(7):847-56. Abstract
S
Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C et al..  2016.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.. The Lancet. Oncology. Abstract